作　　者： (王喜梅）; (明志浩）; (尹辉明）; (蒲艳春）; (刘方）;

机构地区： 湖南医药学院基础医学院,湖南怀化418000

出　　处： 《中华医院感染学杂志》 2017年第15期3597-3600,共4页

摘　　要： 脓毒血症是世界上常见的、致命的、治疗费用高昂的疾病,老龄人口中尤其常见,且不同程度地影响患有癌症和潜在免疫抑制的患者;严重脓毒血症可导致多种器官功能障碍,以致产生以严重的免疫功能和分解代谢障碍为特征的慢性危重疾病状态;目前为此,很难找到一个单一的适合所有脓毒血症的方法;由于支持性医护的改善,包括快速识别脓毒血症和交付有效的抗菌药物、治疗早期脓毒性休克的流体复苏疗法、肺保护性通气、休克解决后更谨慎地使用流体治疗、更明智地使用血液制品以及减少院内二次感染,脓毒血症的预后情况已有效改善;新型治疗途径主要针对器官功能障碍,为了减少异质性及增强新疗法治疗效果,选择脓毒血症患者并将其表型用于临床试验的临床标准和生物标准需要改善。 Sepsis is a common,fatal,and costly disease in the world,particularly common among elder people,and affects patients with cancer and potential immunosuppression in varying degrees.Severe sepsis can lead to a variety of organ dysfunction,resulting in severe immune function and metabolic disorders characterized by chronic critical disease status.At present,it is difficult to find a single method for all sepsis.Due to the improvement in supportive care,including rapid identification of sepsis and delivery of effective antimicrobial agents,treatment of early septic shock fluid resuscitation therapy,pulmonary protective ventilation,shock treatment after more careful use of fluid therapy,more sensible use of blood products and reduce the secondary infection in the hospital,the prognosis of sepsis has been effectively improved.The new treatment approach is mainly for organ dysfunction.In order to reduce the heterogeneity and enhance the efficacy of new therapies,the selection of clinical standards and biomarkers for sepsis patients and their phenotype for clinical trials needs to be improved.

关 键 词： 脓毒血症 流行病学 临床治疗